These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 12506608)

  • 1. [Modern approaches to pharmacotherapy of diabetes mellitus type II].
    Kovel'man IR; Tochilkin AI; Beliaeva NF; Gorodetskiĭ VK; Kniazhev VA; Tkachenko SB; Semenov LL; Semenova NV
    Vopr Med Khim; 2002; 48(4):337-52. PubMed ID: 12506608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vanadium compounds--a new class of therapeutic agents for the treatment of diabetes mellitus].
    Beliaeva NF; Gorodetskiĭ VK; Tochilkin AI; Golubev MA; Semenova NV; Kovel'man IR
    Vopr Med Khim; 2000; 46(4):344-60. PubMed ID: 11075417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 2007 Jan; 41(1):51-60. PubMed ID: 17190843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The present and future of treatment with oral antidiabetic agents].
    Rybka J
    Cas Lek Cesk; 1998 Mar; 137(5):137-44. PubMed ID: 9588096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus.
    Koski RR
    Diabetes Educ; 2006; 32(6):869-76. PubMed ID: 17102154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of bis(alpha-furancarboxylato)oxovanadium(IV) on glucose metabolism in fat-fed/streptozotocin-diabetic rats.
    Niu Y; Liu W; Tian C; Xie M; Gao L; Chen Z; Chen X; Li L
    Eur J Pharmacol; 2007 Oct; 572(2-3):213-9. PubMed ID: 17651728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vanadium salts as insulin substitutes: mechanisms of action, a scientific and therapeutic tool in diabetes mellitus research.
    Sekar N; Li J; Shechter Y
    Crit Rev Biochem Mol Biol; 1996 Dec; 31(5-6):339-59. PubMed ID: 8994801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral antidiabetic drugs].
    Tauber JP
    Rev Prat; 1999 Jan; 49(1):46-50. PubMed ID: 9926716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type II diabetes: insulin versus oral agents.
    Martin DB
    N Engl J Med; 1986 May; 314(20):1314-5. PubMed ID: 3517646
    [No Abstract]   [Full Text] [Related]  

  • 10. Beta-cell apoptosis in type 2 diabetes: quantitative and functional consequences.
    Lupi R; Del Prato S
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S56-64. PubMed ID: 18640587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Arylalkylamine vanadium salts as new anti-diabetic compounds.
    Zorzano A; Palacín M; Marti L; García-Vicente S
    J Inorg Biochem; 2009 Apr; 103(4):559-66. PubMed ID: 19246098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of oral hypoglycemic agents in patients with chronic kidney failure].
    Libardi F; Sirolli V; Cappelli P; Bonomini M
    G Ital Nefrol; 2009; 26(6):679-85. PubMed ID: 19918750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral antidiabetic therapy in patients with heart disease. A cardiologic standpoint.
    Fisman EZ; Tenenbaum A; Motro M; Adler Y
    Herz; 2004 May; 29(3):290-8. PubMed ID: 15167955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning pharmacologic therapy from oral agents to insulin for type 2 diabetes.
    Tanenberg RJ
    Curr Med Res Opin; 2004 Apr; 20(4):541-53. PubMed ID: 15119992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease.
    Henry RR
    Curr Med Res Opin; 2008 Aug; 24(8):2189-202. PubMed ID: 18573228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
    Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Oral antidiabetic drugs in 2003].
    Ducobu J
    Rev Med Brux; 2003 Sep; 24(4):A361-8. PubMed ID: 14606302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Devices for insulin administration.
    Hill J
    Nurs Times; 2003 Apr 15-21; 99(15):51-2. PubMed ID: 12733296
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Triple oral therapy in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2005 Aug; 1(30):1942, 1944-6, 1948. PubMed ID: 16200937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.